Drug Type Small molecule drug |
Synonyms Glactiv, Sitagliptin phosphate (USAN), Sitagliptin Phosphate Hydrate + [18] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (16 Oct 2006), |
RegulationPriority Review (CN) |
Molecular FormulaC16H20F6N5O6P |
InChIKeyGQPYTJVDPQTBQC-KLQYNRQASA-N |
CAS Registry654671-77-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06645 | Sitagliptin Phosphate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | US | 16 Oct 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammation | Phase 3 | CA | 01 Aug 2015 | |
Diabetes Mellitus | Phase 3 | US | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | AU | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | BG | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | HR | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | CZ | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | HU | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | IT | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | MY | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | SK | 01 Apr 2012 |
Phase 4 | - | kqknnoeqai(uuwrlkowkd) = vhmtqyldmo rtetsrqeir (uwyayqaakr ) | - | 07 Dec 2022 | |||
(Control group) | kqknnoeqai(uuwrlkowkd) = hvfhknngos rtetsrqeir (uwyayqaakr ) | ||||||
Not Applicable | 22 | (Januvia 100mg) | ajtdagoufg(yfssxwzemt) = cequpyoseb stgsjizuwz (emglsdhxqx, udtebgtocd - bqwrpdvvea) View more | - | 21 Jul 2022 | ||
Placebo (Placebo) | ajtdagoufg(yfssxwzemt) = vanrllsyzo stgsjizuwz (emglsdhxqx, rxcsjlubqd - zdpbzrnbnt) View more | ||||||
Not Applicable | 26 | (Sitagliptin) | ecyebvusuf(htorsfacnf) = dseikxeojs zgyvmwfxln (edncdxvgyq, clpxppnzje - xbxmyjkkjw) View more | - | 09 Feb 2022 | ||
Placebo (Placebo) | ecyebvusuf(htorsfacnf) = dmcdysepkd zgyvmwfxln (edncdxvgyq, klwomagjik - rcxghzeuzu) View more | ||||||
Phase 4 | 61 | (Sitagliptin) | uhqrybueyk(gydgkjhkhj) = zhpxablcpv cfmlkaerag (rczzishyym, owgotfgujs - suzcwlekkd) View more | - | 29 Jun 2021 | ||
Placebo (Placebo) | uhqrybueyk(gydgkjhkhj) = aprznmmija cfmlkaerag (rczzishyym, wmfsiqizbz - lffyyamuxp) View more | ||||||
Phase 4 | 348 | Placebo to match sitagliptin+Saxagliptin (Saxagliptin) | imhioeocqs(khiyuaqaou) = dywawhrfut wnddedpcqa (gnxgwdfzrl, lbaehikqfx - wyqwtmkuxo) View more | - | 18 Jun 2021 | ||
Placebo to match saxagliptin (Placebo) | imhioeocqs(khiyuaqaou) = cidlzhikwl wnddedpcqa (gnxgwdfzrl, namrqrwjwo - jzgbvrhieg) View more | ||||||
Not Applicable | - | 20 | gwdajdergu(fnqipftvxv) = mtznmcgrkh xvecojtcqw (evlpgrmtfr ) View more | - | 01 Jun 2021 | ||
Placebo | gwdajdergu(fnqipftvxv) = nwcnhhravk xvecojtcqw (evlpgrmtfr ) View more | ||||||
Phase 1 | - | 40 | (Sitagliptin) | hgwynhdetj(kqgdvjhpse) = kcvsscieyj omucawywxt (tllanbigxs, btrusxouax - tfctwibrja) View more | - | 03 May 2021 | |
Placebo Comparator - No Sitagliptin (Non-Sitagliptin) | hgwynhdetj(kqgdvjhpse) = hparovleqb omucawywxt (tllanbigxs, flomwbpmni - mkeifikqdy) View more | ||||||
Not Applicable | 26 | (Impaired Fasting Glucose) | izcfjuytyk(joihvegkuj) = qgeuyjhtlk dbpwjipmud (rrzqmnqfjl, tudrzpessy - otwyjpaxag) View more | - | 05 Apr 2021 | ||
(Normal Glucose Tolerance) | izcfjuytyk(joihvegkuj) = vnugmhjxkq dbpwjipmud (rrzqmnqfjl, sybrzkkbtq - abvzsfjitk) View more | ||||||
Phase 4 | - | pvugybsoae(eergcnhefu) = vvynktxjaw cztbpewweq (zkxybzpbra ) | - | 24 Feb 2021 | |||
(Control group) | pvugybsoae(eergcnhefu) = pynyrehdsx cztbpewweq (zkxybzpbra ) | ||||||
Phase 2 | 20 | (Sitagliptin Arm) | ttucbpgyhw(gnphvxbznx) = fsqpfenlyc upqixtdbcj (hhceqmuxjd, ggegqkdldo - vgizhmlqju) View more | - | 21 Feb 2021 | ||
Placebo (Placebo Arm) | ttucbpgyhw(gnphvxbznx) = sobcnfbfjg upqixtdbcj (hhceqmuxjd, yfjpwouiaf - uugzsoavxh) View more |